CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Non-Hodgkins Lymphoma
Phase 2 Unknown
82 enrolled
MITRAS
Phase 2 Unknown
140 enrolled
MoTD
Phase 2 Unknown
400 enrolled
Intrathecal Rituximab With Standard Intrathecal Prophylaxis to Prevent CNS Relapse for CD 20+ Non Hodgkin Lymphoma
Phase 2 Unknown
20 enrolled
Zevalin Before Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Phase 2 Unknown
20 enrolled
Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma
Phase 2 Unknown
33 enrolled
ZR2-CHOP
Phase 2 Unknown
36 enrolled
A Study of CD19/22 CART Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Lymphoma
Phase 2 Unknown
10 enrolled
CAR-T for R/R B-NHL
Phase 2 Unknown
10 enrolled
Trial of DA-EPOCH Regimen for NHL With HLH
Phase 2 Unknown
50 enrolled
ProT4
Phase 2 Unknown
114 enrolled
EPIC
Phase 2 Unknown
27 enrolled
Chidamide Combined With Clad/Gem/Bu With AutoSCT in High Risk Hodgkin & Non-Hodgkin Lymphoma
Phase 2 Unknown
30 enrolled
BeEAC-1
Phase 2 Unknown
100 enrolled
Phase II of High-dose Therapy in Elderly Patients With Relapsed Aggressive NHL or Resistant to First Line Therapy
Phase 2 Unknown
135 enrolled
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Phase 2 Unknown
63 enrolled
Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation
Phase 2 Unknown
20 enrolled
BEB Conditioning Regimen for Autologous Stem-cell Transplantation(ASCT) in Non-Hodgkin's Lymphoma
Phase 2 Unknown
20 enrolled
Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
Phase 2 Unknown
40 enrolled
Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies
Phase 2 Unknown
24 enrolled
Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma
Phase 2 Unknown
42 enrolled
Study of Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat T Cell or Natural Killer (NK) Cell Lymphoma
Phase 2 Unknown
42 enrolled
Valproic Acid in Treating Patients With Previously Treated Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Chronic Lymphocytic Leukemia
Phase 2 Unknown
52 enrolled
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
Phase 2 Unknown
10 enrolled
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders
Phase 2 Unknown
52 enrolled
Combination Chemotherapy and Radiation Therapy Plus Bone Marrow Transplantation in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 2 Unknown
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia
Phase 2 Unknown
30 enrolled
Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma
Phase 2 Unknown
Combination Chemotherapy Plus Rituximab in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
Phase 2 Unknown
Arsenic Trioxide in Treating Patients With Recurrent or Refractory Acute Leukemia, Chronic Myeloide Leukemia, Myelodysplasia, Lymphoma, or Myeloma
Phase 2 Unknown
60 enrolled
Combination Chemotherapy in Treating Patients With Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma Who Have Not Responded to Anthracycline-Containing Combination Chemotherapy
Phase 2 Unknown
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases
Phase 2 Unknown
60 enrolled
REAL07
Phase 2 Unknown
49 enrolled
LNH-RGDOX
Phase 2 Unknown
50 enrolled
BuEAM Conditioning for Autologous Stem Cell Transplantation (ASCT) to Treat Diffuse Large B Cell Lymphoma (DLCBL)
Phase 2 Unknown
42 enrolled
High-dose Chemotherapy and Stem Cell Transplantation for Central Nervous System (CNS) Relapse of Aggressive Lymphomas
Phase 2 Unknown
30 enrolled
Stem Cell Transplant in Treating Patients With Hematological Cancer or Other Disorders
Phase 2 Unknown
50 enrolled
HD-MCL2003
Phase 2 Unknown
20 enrolled
Pixantrone, Cytarabine, Methylprednisolone, and Cisplatin in Treating Patients With Aggressive Non-Hodgkin's Lymphoma in First Relapse
Phase 2 Unknown
BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma
Phase 2 Unknown
KLYMF
Phase 2 Unknown
45 enrolled
Zevalin
Phase 2 Unknown
40 enrolled
Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL
Phase 2 Unknown
30 enrolled
A Dose Study of Doxil in a Dose Dense, 14 Day CDOP/Rituximab Regimen for Patients With Diffuse Large B-Cell Non-Hodgkin Lymphoma (NHL)> 60 Years or With Compromised Cardiac Status.
Phase 2 Unknown
27 enrolled
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP
Phase 2 Unknown
Idiotype Vaccine for Low-Grade Non-Hodgkin's Lymphoma
Phase 2 Unknown
22 enrolled
Xcellerated T CellsTM for Non-Hodgkin's Lymphoma (NHL) Patients
Phase 2 Unknown
40 enrolled